Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells
Screening and Genetic Monitoring of Patients With MDS Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells
Sponsor: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
This observational or N/A phase trial investigates Chromosmal Aberrations and Cytogenetic Monitoring and is currently completed. Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Mar 2020 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Feb 2019 — Mar 2020 [monthly]
Active Not Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Nov 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Nov 2017 [monthly]
Active Not Recruiting NA
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
- University Medical Center Goettingen
For direct contact, visit the study record on ClinicalTrials.gov .